Looking for a come-from-behind win, Roche touts its pivotal success for Tecentriq combo in front-line lung cancer
Trailing far behind Merck $MRK and Bristol-Myers Squibb $BMY, the leaders in the heated showdown for market supremacy in the PD-1/L1 commercial race, Roche is making its move in the key lung cancer market with a set of promising, progression-free survival data for a combination using Tecentriq.
Their closely watched Phase III IMpower150 study of a triple combo of Tecentriq, Avastin and chemo demonstrated a doubling in 12-month progression-free survival rates among a broad group of frontline lung cancer patients, setting the stage for a quick regulatory OK on both sides of the Atlantic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
